Thus, targeting Prx II have potential therapeutic effects to treat colorectal cancers with and without APC mutations as it is already proved the increasing sensitivities of colon cancers to existing chemo and radiotherapy by inhibiting Prx II expression [94,100]. This evidence concerns the gene APC and malignant colon neoplasm.